Remdesivir was recently given to US Prez and he showed improvements. World Health Organisation (WHO) is required to soon issue policy guidelines on the use of anti-viral drug Remdesivir. The drug has been given urgency to use authorization in many countries including the US. However, the latest tests recommend that the drug has almost no effect in stopping fatalities, and therefore requires policy changes. As per the NKA World report, the WHO has said that the interim results from a clinical trial which it coordinated show that Remdesivir has little or no effect in preventing death from COVID-19 or reducing time in hospital.
The trial was carried out in more than 400 hospitals in 30 countries, as stated. The full results of the trials are to be announced shortly, WHO Director-General Tedros Adhanom Ghebreyesus said at a press conference. What the United Nations (UN) health agency called “world’s largest randomized control trial” on COVID-19 therapeutics, which lasted for six months, has generated conclusive evidence on the effectiveness of repurposed medications - Remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon for treating COVID-19 patients.
In a surprise finding, WHO decided that these four COVID-19 therapeutics “appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.” Spanning in over 30 countries, the ‘Solidarity Therapeutics Trial’ overseen by WHO had begun in March to monitor the effects of these treatments on overall mortality, need for ventilation, along with the duration for which the patient is required to hospitalized.